Sign in Subscribe
Drugs

Diversa Corp. and Aventis Extend Research Agreement for Biocatalytic Process Development

Strategic Insights

— 1 min read

Diversa Corp. and Aventis Animal Nutrition S.A., a subsidiary of Aventis S.A., announced an extension of their research agreement to develop a biocatalytic process for manufacturing a key Aventis product for animal nutrition. This extension will provide additional research funding to Diversa, furthering their collaborative efforts to optimize the biocatalyst. Aventis has developed a unique manufacturing process, and Diversa is utilizing its proprietary evolution and screening technologies to refine the biocatalyst. This partnership is part of Diversa's strategy to develop novel enzymes and genes from diverse environmental sources.

Key Takeaways:

  • Diversa Corp. and Aventis Animal Nutrition S.A. have extended their research agreement to develop a biocatalytic process for manufacturing a key Aventis product for animal nutrition.
  • The partnership will provide additional research funding to Diversa, allowing for further optimization of the biocatalyst.
  • Aventis has developed a unique manufacturing process, and Diversa is utilizing its proprietary evolution and screening technologies to refine the biocatalyst.
  • Diversa's powerful, proprietary evolution technologies can generate ideal product solutions across various markets, including agricultural, chemical processing, industrial, and pharmaceutical.
  • The company's strategic partners include Novartis Seeds AG, Novartis Agribusiness Biotechnology Research Inc., The Dow Chemical Co., Finnfeeds International Limited, and Aventis Animal Nutrition S.A.
  • Aventis S.A. is a world leader in life sciences, with a focus on pharmaceuticals and agriculture, and recorded sales in 1999 of more than euro 18 billion.

Statistics:

  • The partnership will focus on developing a biocatalytic process for manufacturing a key Aventis product for animal nutrition.
  • An additional research funding was secured for Diversa without disclosing the specific terms.
  • Aventis S.A. recorded sales in 1999 of more than euro 18 billion.
  • Diversa's collaboration with Aventis will contribute to the company's global expansion and its vision to improve life through innovative products.
  • The partnership will leverage Diversa's proprietary technologies and Aventis's expertise to create high-value products.

Sources:

  • "Business Editors and Health/Medical Writers BIOWIRE2K SAN DIEGO--(BW HealthWire)--April 13, 2000 Diversa Corp. (Nasdaq:DVSA)..."

Read more